This data is consistent with expansion in functional specificities in the peripheral blood following anti-CTLA4 therapy (194), but little evidence of correlation between clonotypic changes in the peripheral blood versus the tumor following anti-CTLA4 therapy (195). This evidence concerns the gene CTLA4 and neoplasm.